{"DataElement":{"publicId":"14741263","version":"1","preferredName":"Diagnosis Disease or Disorder WHO CNS5 Integrated Diagnosis Text","preferredDefinition":"Words which describe the classification of central nervous system neoplasms defined by the combination of molecular diagnostics with histopathological and immunohistochemical findings.","longName":"11344530v1.00:14737393v1.00","context":"Pediatric Cancer","contextVersion":"1","DataElementConcept":{"publicId":"11344530","version":"1","preferredName":"Diagnosis Disease or Disorder","preferredDefinition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","longName":"2442484v1.00:2239878v1.00","context":"CRDC","contextVersion":"1","ObjectClass":{"publicId":"2442484","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"09046428-50E1-6C1D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-01-04","modifiedBy":"ONEDATA","dateModified":"2006-01-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2239878","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FA7953-827F-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-24","modifiedBy":"ONEDATA","dateModified":"2005-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CRDC:Cancer Research Data Commons","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E9EB1168-355C-05ED-E053-731AD00AC8E3","latestVersionIndicator":"Yes","beginDate":"2022-09-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2022-09-30","modifiedBy":"SOKKERL","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":"2/20/24 AI released per SME/Amanda Bell approval.ls11/18/22 Released per CRDC DSS. mr; \r\n9/30/22 Created per CRDC DSS. mr","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"14737393","version":"1","preferredName":"WHO CNS5 Integrated Diagnosis Text","preferredDefinition":"A term that refers to the WHO 5th edition classification of central nervous system neoplasms defined by the combination of molecular diagnostics with histopathological and immunohistochemical findings._The words of something written.","longName":"14737393v1.00","context":"Pediatric Cancer","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Adamantinomatous Craniopharyngioma","valueDescription":null,"ValueMeaning":{"publicId":"5043586","version":"1","preferredName":"Adamantinomatous Craniopharyngioma","longName":"5043586","preferredDefinition":"A craniopharyngioma consisting of broad strands, cords and bridges of a multistratified squamous epithelium with peripheral palisading of nuclei. Diagnostic features include nodules of compact 'wet' keratin and dystrophic calcification. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adamantinomatous Craniopharyngioma","conceptCode":"C4726","definition":"A craniopharyngioma consisting of broad strands, cords and bridges of a multistratified squamous epithelium with peripheral palisading of nuclei. Diagnostic features include nodules of compact 'wet' keratin and dystrophic calcification. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24332DE1-109D-F0BF-E050-BB89AD4319C0","latestVersionIndicator":"Yes","beginDate":"2015-11-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-10","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-4FFF-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Angiocentric Glioma","valueDescription":null,"ValueMeaning":{"publicId":"5043584","version":"1","preferredName":"Angiocentric Glioma","longName":"5043584","preferredDefinition":"A WHO grade I, slow-growing brain neoplasm of children and young adults, associated with epilepsy.  Morphologically it is characterized by an angiocentric pattern, monomorphic cellular infiltrate, and ependymal differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Angiocentric Glioma","conceptCode":"C92552","definition":"A WHO grade 1, slow-growing brain neoplasm of children and young adults, associated with epilepsy.  Morphologically it is characterized by an angiocentric pattern, monomorphic cellular infiltrate, and ependymal differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24332DE1-1043-F0BF-E050-BB89AD4319C0","latestVersionIndicator":"Yes","beginDate":"2015-11-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-10","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5000-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Astrocytoma, IDH-Mutant","valueDescription":null,"ValueMeaning":{"publicId":"14235586","version":"1","preferredName":"Astrocytoma, IDH-Mutant","longName":"14235586v1.00","preferredDefinition":"An astrocytoma associated with IDH1 or IDH2 gene mutations and absence of 1p/19q codeletion. It is classified as grade 2, 3, or 4.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Astrocytoma, IDH-Mutant","conceptCode":"C185167","definition":"An astrocytoma associated with IDH1 or IDH2 gene mutations and absence of 1p/19q codeletion. It is classified as grade 2, 3, or 4.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1D5-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5001-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Cerebellar Liponeurocytoma","valueDescription":null,"ValueMeaning":{"publicId":"2578720","version":"1","preferredName":"Cerebellar liponeurocytoma","longName":"2578720","preferredDefinition":"Cerebellar Liponeurocytoma (WHO grade I or II) is a rare cerebellar neoplasm which shows advanced neuronal/neurocytic and focal lipomatous differentiation. It occurs in adults, has a low proliferative potential and has a favorable clinical prognosis. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerebellar Liponeurocytoma","conceptCode":"C6905","definition":"A rare, WHO grade II cerebellar neoplasm which shows consistent neuronal, variable astrocytic and focal lipomatous differentiation. It occurs in adults, has a low proliferative potential and usually has a favorable prognosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-008D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-10","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2004-03-10","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5002-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Chondrosarcoma","valueDescription":null,"ValueMeaning":{"publicId":"3179236","version":"1","preferredName":"Chondrosarcoma","longName":"3179236","preferredDefinition":"A malignant mesenchymal tumor arising from cartilage-forming tissues involving the bones.  It affects middle-aged to elderly adults, and the pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement.  Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chondrosarcoma","conceptCode":"C2946","definition":"A malignant cartilaginous matrix-producing mesenchymal neoplasm arising from the bone and soft tissue.  It usually affects middle-aged to elderly adults.  The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement.  Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9881C41C-CDA1-C63B-E040-BB89AD437873","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-28","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5003-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Chordoid Glioma","valueDescription":null,"ValueMeaning":{"publicId":"13628855","version":"1","preferredName":"Chordoid Glioma","longName":"13628855v1.00","preferredDefinition":"A rare, slow-growing neuroepithelial neoplasm of uncertain origin affecting adults. It is located in the third ventricle. It is characterized by the presence of epithelioid cells which express GFAP, and mucinous stroma which contains lymphoplasmacytic infiltrates.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chordoid Glioma","conceptCode":"C5592","definition":"A rare, slow-growing neuroepithelial neoplasm of uncertain origin affecting adults. It is located in the third ventricle. It is characterized by the presence of epithelioid cells which express GFAP, and mucinous stroma which contains lymphoplasmacytic infiltrates.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC5EF0E0-6FD2-73C4-E053-731AD00AE77A","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-23","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5004-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Choroid Plexus Carcinoma","valueDescription":null,"ValueMeaning":{"publicId":"2578711","version":"1","preferredName":"Choroid plexus carcinoma","longName":"2578711","preferredDefinition":"Choroid Plexus Carcinoma (WHO grade III) is a malignant Choroid Plexus Tumor which shows anaplastic features and usually invades neighboring brain structures. CSF metastases are frequent. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choroid Plexus Carcinoma","conceptCode":"C4715","definition":"A malignant neoplasm arising from the choroid plexus.  It shows anaplastic features and usually invades neighboring brain structures. Cerebrospinal fluid metastases are frequent. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0084-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5005-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Choroid Plexus Papilloma","valueDescription":null,"ValueMeaning":{"publicId":"2572938","version":"1","preferredName":"Choroid Plexus Papilloma","longName":"2572938","preferredDefinition":"Choroid Plexus Papilloma (WHO grade I) is a benign, slow growing tumor which may cause symptoms by blocking CSF pathways. Surgical resection is usually curative. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choroid Plexus Papilloma","conceptCode":"C3698","definition":"A benign, slow growing tumor which may cause symptoms by blocking cerebrospinal fluid pathways.  It is characterized by the presence of delicate fibrovascular connective tissue fronds covered by a single layer of epithelial cells.  Mitotic activity is extremely low.  Surgical resection is usually curative. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9F7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5006-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"CIC-Rearranged Sarcoma","valueDescription":null,"ValueMeaning":{"publicId":"14235570","version":"1","preferredName":"CIC-Rearranged Sarcoma","longName":"14235570v1.00","preferredDefinition":"An undifferentiated, high grade small round cell sarcoma affecting predominantly young adults. It is characterized by a recurrent translocation involving the CIC gene on chromosome 19 and either DUX4 gene on chromosome 4 or DUX4L gene on chromosome 10. The translocation results in either CIC-DUX4, t(4;19)(q35;q13) or CIC-DUX4L, t(10;19)(q26;q13) fusions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CIC-Rearranged Sarcoma","conceptCode":"C120224","definition":"An undifferentiated, high grade small round cell sarcoma affecting predominantly young adults. It is characterized by a recurrent translocation involving the CIC gene on chromosome 19 and either DUX4 gene on chromosome 4 or DUX4L gene on chromosome 10. The translocation results in either CIC-DUX4, t(4;19)(q35;q13) or CIC-DUX4L, t(10;19)(q26;q13) fusions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF7926-1F5B-717F-E063-731AD00A089A","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5007-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Diffuse Glioneuronal Tumor with Oligodendroglioma-Like Features and Nuclear Clusters","valueDescription":null,"ValueMeaning":{"publicId":"14236696","version":"1","preferredName":"Diffuse Glioneuronal Tumor with Oligodendroglioma-Like Features and Nuclear Clusters","longName":"14236696v1.00","preferredDefinition":"A provisional tumor entity described in the supratentorial brain and characterized by a distinct DNA methylation profile and monosomy of chromosome 14. It is composed of small to medium-sized cells showing perinuclear oligodendroglioma-like haloes, scattered multinucleated cells, and nuclear clusters composed of large pleomorphic nuclei. Most cases have been reported in pediatric patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Glioneuronal Tumor with Oligodendroglioma-Like Features and Nuclear Clusters","conceptCode":"C185935","definition":"A provisional tumor entity described in the supratentorial brain and characterized by a distinct DNA methylation profile and monosomy of chromosome 14. It is composed of small to medium-sized cells showing perinuclear oligodendroglioma-like haloes, scattered multinucleated cells, and nuclear clusters composed of large pleomorphic nuclei. Most cases have been reported in pediatric patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01DF4647-31FD-6D56-E063-731AD00A33C7","latestVersionIndicator":"Yes","beginDate":"2023-08-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-01","modifiedBy":"GDEEN","dateModified":"2023-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5008-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Diffuse Hemispheric Glioma, H3 G34-Mutant","valueDescription":null,"ValueMeaning":{"publicId":"14235244","version":"1","preferredName":"Diffuse Hemispheric Glioma, H3 G34-Mutant","longName":"14235244v1.00","preferredDefinition":"A WHO grade 4 diffuse glioma arising in the cerebral hemispheres. It is characterized by the presence of missense mutation of the H3-3A gene. The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Hemispheric Glioma, H3 G34-Mutant","conceptCode":"C185371","definition":"A WHO grade 4 diffuse glioma arising in the cerebral hemispheres. It is characterized by the presence of missense mutation of the H3-3A gene. The prognosis is poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CBA8C7-0CA1-4A47-E063-731AD00A98B9","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"LISU","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5009-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Diffuse Leptomeningeal Glioneuronal Tumor","valueDescription":null,"ValueMeaning":{"publicId":"14235579","version":"1","preferredName":"Diffuse Leptomeningeal Glioneuronal Tumor","longName":"14235579v1.00","preferredDefinition":"A relatively slow growing diffuse leptomeningeal neoplasm usually affecting children and adolescents. It is characterized by the presence of clear glial neoplastic cells reminiscent of oligodendroglioma. A neuronal component may be present. The prognosis is variable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Leptomeningeal Glioneuronal Tumor","conceptCode":"C129424","definition":"A relatively slow growing diffuse leptomeningeal neoplasm usually affecting children and adolescents. It is characterized by the presence of clear glial neoplastic cells reminiscent of oligodendroglioma. A neuronal component may be present. The prognosis is variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF7C0B-B1F6-71EF-E063-731AD00A2DF2","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-500A-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Diffuse Midline Glioma, H3 K27-Altered","valueDescription":null,"ValueMeaning":{"publicId":"14235243","version":"1","preferredName":"Diffuse Midline Glioma, H3 K27-Altered","longName":"14235243v1.00","preferredDefinition":"A diffuse midline glioma characterized by H3 K27 alteration and usually either a histone H3 K27M mutation, an EGFR mutation, or aberrant overexpression of EZHIP. The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Midline Glioma, H3 K27-Altered","conceptCode":"C185368","definition":"A diffuse midline glioma characterized by H3 K27 alteration and usually either a histone H3 K27M mutation, an EGFR mutation, or aberrant overexpression of EZHIP. The prognosis is poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CBA8C7-0CA0-4A47-E063-731AD00A98B9","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"LISU","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-500B-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Dysembryoplastic Neuroepithelial Tumor","valueDescription":null,"ValueMeaning":{"publicId":"2578718","version":"1","preferredName":"Dysembryoplastic Neuroepithelial Tumor","longName":"2578718","preferredDefinition":"Dysembryoplastic Neuroepithelial Tumor (WHO grade I) is a benign glial-neuronal neoplasm. It is usually supratentorial, located, generally, in the cortex and occurs in children and young adults with a long-standing history of partial seizures. A histologic hallmark of this tumor is the 'specific glioneuronal element', characterized by columns, made up of bundles of axons, oriented perpendicularly to the cortical surface. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysembryoplastic Neuroepithelial Tumor","conceptCode":"C9505","definition":"A glial-neuronal neoplasm located in the cortex. It occurs in children and young adults with a long-standing history of partial seizures. A histologic hallmark of this tumor is the 'specific glioneuronal element', characterized by columns, made up of bundles of axons, oriented perpendicularly to the cortical surface. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-008B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-500C-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Erdheim-Chester Disease","valueDescription":null,"ValueMeaning":{"publicId":"13628847","version":"1","preferredName":"Erdheim-Chester Disease","longName":"13628847v1.00","preferredDefinition":"A very rare, multisystem non-Langerhans cell histiocytosis that predominantly affects adults.  It is characterized by the proliferation in the tissues of lipid-laden macrophages and the presence of multinucleated giant cells.  It results in sclerosis of the long bones and failure of the affected organs.  Patients may present with bone pain, exophthalmos, ataxia, liver failure, kidney failure, and hypopituitarism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erdheim-Chester Disease","conceptCode":"C53972","definition":"A very rare, multisystem non-Langerhans cell histiocytosis that predominantly affects adults.  It is characterized by the proliferation in the tissues of lipid-laden macrophages and the presence of multinucleated giant cells.  It results in sclerosis of the long bones and failure of the affected organs.  Patients may present with bone pain, exophthalmos, ataxia, liver failure, kidney failure, and hypopituitarism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC5EECF7-BF2F-7357-E053-731AD00AC348","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-23","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-500D-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Ewing Sarcoma","valueDescription":null,"ValueMeaning":{"publicId":"2593150","version":"1","preferredName":"Ewing Sarcoma","longName":"2593150","preferredDefinition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ewing Sarcoma","conceptCode":"C4817","definition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6E8E-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-500E-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Extraventricular Neurocytoma","valueDescription":null,"ValueMeaning":{"publicId":"14235581","version":"1","preferredName":"Extraventricular Neurocytoma","longName":"14235581v1.00","preferredDefinition":"A WHO grade 2 neoplasm that arises from the brain parenchyma. Morphologically it is characterized by the presence of neoplastic uniform, round cells with neuronal differentiation. Unlike central neurocytoma, it does not involve the lateral ventricles. It usually affects young adults and has a favorable prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extraventricular Neurocytoma","conceptCode":"C92555","definition":"A WHO grade 2 neoplasm that arises from the brain parenchyma. Morphologically it is characterized by the presence of neoplastic uniform, round cells with neuronal differentiation. Unlike central neurocytoma, it does not involve the lateral ventricles. It usually affects young adults and has a favorable prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF7C0B-B1F8-71EF-E063-731AD00A2DF2","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-500F-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Gangliocytoma","valueDescription":null,"ValueMeaning":{"publicId":"2578713","version":"1","preferredName":"Gangliocytoma","longName":"2578713","preferredDefinition":"Gangliocytoma (WHO grade I) and Ganglioglioma (WHO grade I or II) are well differentiated, slow growing neuroepithelial neoplasms composed of neoplastic, mature ganglion cells either alone (gangliocytoma), or in combination with neoplastic glial cells (ganglioglioma). (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gangliocytoma","conceptCode":"C6934","definition":"A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0086-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5010-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Ganglioglioma","valueDescription":null,"ValueMeaning":{"publicId":"2578714","version":"1","preferredName":"Ganglioglioma","longName":"2578714","preferredDefinition":"Ganglioglioma (WHO grade I or II) and Gangliocytoma (WHO grade I) are well differentiated, slow growing neuroepithelial neoplasms composed of neoplastic, mature ganglion cells either alone (gangliocytoma), or in combination with neoplastic glial cells (ganglioglioma). Some Gangliogliomas show anaplastic features in their glial component and are considered to be WHO grade III (see 'Anaplastic Ganglioglioma). There are rare cases of newly diagnosed Gangliogliomas with grade IV (Glioblastoma) changes in the glial component. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganglioglioma","conceptCode":"C3788","definition":"A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and neoplastic glial cells. Some gangliogliomas show anaplastic features in their glial component and are considered to be WHO grade III. Rare cases of newly diagnosed gangliogliomas with grade IV (glioblastoma) changes in the glial component have also been reported. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0087-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5011-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Glioblastoma, IDH-Wildtype","valueDescription":null,"ValueMeaning":{"publicId":"5698562","version":"1","preferredName":"Glioblastoma, IDH-Wildtype","longName":"5698562v1.00","preferredDefinition":"A glioblastoma that arises de novo. It is more commonly seen in older patients. Mutations in IDH1 or IDH2 genes are not present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma, IDH-Wildtype","conceptCode":"C39750","definition":"A glioblastoma that arises de novo. It is more commonly seen in older patients. Mutations in IDH1 or IDH2 genes are not present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B273-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5012-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Hemangioblastoma","valueDescription":null,"ValueMeaning":{"publicId":"2838583","version":"1","preferredName":"Capillary Hemangioblastoma","longName":"2838583","preferredDefinition":"A WHO grade I tumor of uncertain histogenesis which is composed of stromal cells and abundant capillaries. Approximately 25% of hemangioblastomas are associated with Von Hippel-Lindau disease, a disease inherited through an autosomal dominant trait and characterized by the development of capillary hemangioblastomas of the central nervous system and retina, clear cell renal carcinoma, pheochromocytoma, and pancreatic and inner ear tumors. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemangioblastoma","conceptCode":"C3801","definition":"A rare, slow-growing tumor of uncertain histogenesis. It affects the central nervous system and infrequently other sites. It is composed of stromal cells and abundant capillaries.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-591E-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5013-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Histiocytic Sarcoma","valueDescription":null,"ValueMeaning":{"publicId":"2864914","version":"1","preferredName":"Histiocytic Sarcoma","longName":"2864914","preferredDefinition":"An aggressive malignant neoplasm with a poor response to therapy, usually presenting as stage III/IV disease.  It is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histiocytic Sarcoma","conceptCode":"C27349","definition":"An aggressive malignant neoplasm with a poor response to therapy, usually presenting as stage III/IV disease. It is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"689FD4E4-A1CC-9A6F-E040-BB89AD432DE8","latestVersionIndicator":"Yes","beginDate":"2009-04-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-28","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5014-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Intravascular Large B-Cell Lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2947252","version":"1","preferredName":"Intravascular Large B-Cell Lymphoma","longName":"2947252","preferredDefinition":"A rare extranodal B-cell non-Hodgkin lymphoma, characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.  This is an extremely aggressive lymphoma which responds poorly to chemotherapy.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravascular Large B-Cell Lymphoma","conceptCode":"C4342","definition":"A rare extranodal B-cell non-Hodgkin lymphoma, characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.  This is an extremely aggressive lymphoma which responds poorly to chemotherapy.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74B9639F-F1F8-0172-E040-BB89AD436135","latestVersionIndicator":"Yes","beginDate":"2009-09-29","endDate":null,"createdBy":"SCOTTLO","dateCreated":"2009-09-29","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5015-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Juvenile Xanthogranuloma","valueDescription":null,"ValueMeaning":{"publicId":"14235557","version":"1","preferredName":"Juvenile Xanthogranuloma","longName":"14235557v1.00","preferredDefinition":"A benign histiocytic tumor that occurs during childhood; it is distinct from Langerhans cell histiocytosis. It is characterized by the presence of lipid-laden, foamy histiocytes and Touton-type giant cells in the dermis.  The lesions usually develop during infancy. They consist of cutaneous papules and nodules (most often in the head and neck). It is sometimes associated with deep soft tissues nodules.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Xanthogranuloma","conceptCode":"C3451","definition":"A benign histiocytic tumor that usually arises from the skin and occurs during childhood; it is distinct from Langerhans cell histiocytosis. It is characterized by the presence of lipid-laden, foamy histiocytes and Touton-type giant cells in the dermis. The lesions usually develop during infancy. While the majority of cases arise from the skin, it can rarely also arise from extracutaneous sites including the eye, ocular adnexa, oral cavity, paranasal sinuses, and ear. It is sometimes associated with deep soft tissues nodules.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF6B9B-848F-703C-E063-731AD00A6B0E","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5016-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Langerhans Cell Histiocytosis","valueDescription":null,"ValueMeaning":{"publicId":"2838588","version":"1","preferredName":"Langerhans Cell Histiocytosis","longName":"2838588","preferredDefinition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Langerhans Cell Histiocytosis","conceptCode":"C3107","definition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F6D7-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5017-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Lymphomatoid Granulomatosis","valueDescription":null,"ValueMeaning":{"publicId":"2838594","version":"1","preferredName":"Lymphomatoid Granulomatosis","longName":"2838594","preferredDefinition":"An angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites, comprised of Epstein-Barr virus (EBV)-positive B-cells admixed with reactive T-cells.  Incidence is higher among adult males; patients with a history of immunodeficiency are at increased risk.  The most common site of involvement is the lung; other common sites include brain, kidney, liver, and skin.  Morphologically, three grades are recognized: grade I, II, and III.  Grade III lymphomatoid granulomatosis should be approached clinically as a subtype of diffuse large B-cell lymphoma. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphomatoid Granulomatosis","conceptCode":"C7930","definition":"An angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites, comprised of Epstein-Barr virus (EBV)-positive B-cells admixed with reactive T-cells.  Incidence is higher among adult males; patients with a history of immunodeficiency are at increased risk.  The most common site of involvement is the lung; other common sites include brain, kidney, liver, and skin.  Morphologically, three grades are recognized: grade I, II, and III.  Grade III lymphomatoid granulomatosis should be approached clinically as a subtype of diffuse large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F7F1-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5018-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Medulloblastoma, Non-WNT/Non-SHH","valueDescription":null,"ValueMeaning":{"publicId":"13628699","version":"1","preferredName":"Medulloblastoma, Non-WNT/Non-SHH","longName":"13628699v1.00","preferredDefinition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. TP53 mutations are absent. This molecular subtype includes medulloblastomas numerically designated as \"group 3\" and \"group 4\".","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma, Non-WNT/Non-SHH","conceptCode":"C129444","definition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. TP53 mutations are absent. This molecular subtype includes medulloblastomas numerically designated as \"group 3\" and \"group 4\".","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC5C17D9-EAE4-7245-E053-731AD00A5A6D","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-23","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5019-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Medulloblastoma, WNT-Activated","valueDescription":null,"ValueMeaning":{"publicId":"4419656","version":"1","preferredName":"WNT signaling pathway aberrant medulloblastoma","longName":"4419656","preferredDefinition":"A molecular subtype of medulloblastoma associated with activation of the WNT pathway. TP53 mutations may be present or absent. WNT pathway activation in medulloblastomas is associated with good outcome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma, WNT-Activated","conceptCode":"C129440","definition":"A molecular subtype of medulloblastoma associated with activation of the WNT pathway. TP53 mutations may be present or absent. WNT pathway activation in medulloblastomas is associated with good outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6D3778-2D69-5529-E040-BB89AD43092C","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-501A-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Meningioma","valueDescription":null,"ValueMeaning":{"publicId":"4265263","version":"1","preferredName":"Meningioma","longName":"4265263","preferredDefinition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade I tumors, and some are WHO grade II or III tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningioma","conceptCode":"C3230","definition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4D52-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-501B-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Myxoid Glioneuronal Tumor","valueDescription":null,"ValueMeaning":{"publicId":"14235578","version":"1","preferredName":"Myxoid Glioneuronal Tumor","longName":"14235578v1.00","preferredDefinition":"A rare, low-grade glioneuronal neoplasm characterized by a dinucleotide mutation at codon 385 of the PDGFR gene. It usually occurs in the septum pellucidum. It has also been described in the corpus callosum and periventricular white matter of the lateral ventricle. It has histologic features reminiscent of either dysembryoplastic neuroepithelial tumor or rosette-forming glioneuronal tumor. It is composed of oligodendrocyte-like cells in a prominent myxoid stroma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myxoid Glioneuronal Tumor","conceptCode":"C179229","definition":"A rare, low-grade glioneuronal neoplasm characterized by a dinucleotide mutation at codon 385 of the PDGFR gene. It usually occurs in the septum pellucidum. It has also been described in the corpus callosum and periventricular white matter of the lateral ventricle. It has histologic features reminiscent of either dysembryoplastic neuroepithelial tumor or rosette-forming glioneuronal tumor. It is composed of oligodendrocyte-like cells in a prominent myxoid stroma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF7C0B-B1F5-71EF-E063-731AD00A2DF2","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-501C-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Papillary Craniopharyngioma","valueDescription":null,"ValueMeaning":{"publicId":"2838035","version":"1","preferredName":"Papillary Craniopharyngioma","longName":"2838035","preferredDefinition":"A craniopharyngioma composed of sheets of squamous epithelium which separate to form pseudopapillae. This variant typically lacks nuclear palisading, wet keratin, calcification, and cholesterol deposits. Clinically, endocrine deficiencies are more often associated with papillary craniopharyngioma than with the adamantinomatous type. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Craniopharyngioma","conceptCode":"C4725","definition":"A craniopharyngioma composed of sheets of squamous epithelium which separate to form pseudopapillae. This variant typically lacks nuclear palisading, wet keratin, calcification, and cholesterol deposits. Clinically, endocrine deficiencies are more often associated with papillary craniopharyngioma than with the adamantinomatous type. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-8453-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-501D-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Papillary Glioneuronal Tumor","valueDescription":null,"ValueMeaning":{"publicId":"5043932","version":"1","preferredName":"Papillary Glioneuronal Tumor","longName":"5043932","preferredDefinition":"A WHO grade I, indolent and relatively circumscribed brain tumor.  Morphologically it is characterized by the presence of astrocytes that line vascular and hyalinized pseudopapillae.  In between the pseudopapillae aggregates of neurocytes, large neurons, and ganglioid cells are present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Glioneuronal Tumor","conceptCode":"C92554","definition":"A WHO grade 1, indolent and relatively circumscribed brain tumor.  Morphologically it is characterized by the presence of astrocytes that line vascular and hyalinized pseudopapillae.  In between the pseudopapillae aggregates of neurocytes, large neurons, and ganglioid cells are present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2436996F-9C02-D051-E050-BB89AD432085","latestVersionIndicator":"Yes","beginDate":"2015-11-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-10","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-501E-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Papillary Tumor of the Pineal Region","valueDescription":null,"ValueMeaning":{"publicId":"5043931","version":"1","preferredName":"Papillary Tumor of the Pineal Region","longName":"5043931","preferredDefinition":"A rare tumor that arises from the pineal region and affects adults.  It is characterized by the presence of neuroepithelial cells and a papillary architecture.  Electron microscopic studies suggest ependymal differentiation.  The clinical course is variable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Tumor of the Pineal Region","conceptCode":"C92624","definition":"A rare tumor that arises from the pineal region and affects adults.  It is characterized by the presence of neuroepithelial cells and a papillary architecture.  Electron microscopic studies suggest ependymal differentiation.  The clinical course is variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2436996F-9BDD-D051-E050-BB89AD432085","latestVersionIndicator":"Yes","beginDate":"2015-11-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-10","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-501F-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Pilocytic Astrocytoma","valueDescription":null,"ValueMeaning":{"publicId":"2578708","version":"1","preferredName":"Pilocytic astrocytoma","longName":"2578708","preferredDefinition":"Pilocytic Astrocytoma, the most common glioma in children, is a WHO grade I astrocytic tumor. It is a generally well circumscribed, slowly growing, often cystic, astrocytoma. It is histologically characterized by a biphasic pattern with varying proportion of compacted bipolar cells which may have Rosenthal fibers (tapered corkscrew-shaped, brightly eosinophilic, intracytoplasmic hyaline masses) and loose textured multipolar cells with microcysts and granular bodies. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pilocytic Astrocytoma","conceptCode":"C4047","definition":"A WHO grade 1, relatively circumscribed, slowly growing, often cystic astrocytoma occurring in children and young adults.  Histologically it is characterized by a biphasic pattern with compacted bipolar cells associated with Rosenthal fibers and multipolar cells associated with microcysts and eosinophilic bodies/hyaline droplets. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0081-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5020-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Pineal Parenchymal Tumor of Intermediate Differentiation","valueDescription":null,"ValueMeaning":{"publicId":"2838665","version":"1","preferredName":"Pineal Parenchymal Tumor of Intermediate","longName":"2838665v1.00","preferredDefinition":"A WHO grade 2 or 3 pineal parenchymal neoplasm of intermediate-grade malignancy, affecting all ages.  It is composed of diffuse sheets or large lobules of uniform cells with mild to moderate nuclear atypia and low to moderate level mitotic activity.  (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pineal Parenchymal Tumor of Intermediate Differentiation","conceptCode":"C6967","definition":"A WHO grade 2 or 3 pineal parenchymal neoplasm of intermediate-grade malignancy, affecting all ages.  It is composed of diffuse sheets or large lobules of uniform cells with mild to moderate nuclear atypia and low to moderate level mitotic activity.  (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A770F5-59FF-03F5-E040-BB89AD435AD2","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5021-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Pineoblastoma","valueDescription":null,"ValueMeaning":{"publicId":"3251836","version":"1","preferredName":"Pineoblastoma","longName":"3251836","preferredDefinition":"Pineoblastoma (WHO grade IV) is a highly malignant, primitive embryonal neoplasm, which occurs more commonly in children. It is composed of patternless sheets of densely packed small cells with round-to-irregular nuclei and scant cytoplasm, similar to medulloblastoma and related primitive neuroectodermal tumors. A frequent complication is metastasis via cerebrospinal fluid pathways, which is often associated with a fatal outcome. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pineoblastoma","conceptCode":"C9344","definition":"A poorly differentiated malignant embryonal neoplasm arising from the pineal region.  It usually occurs in children and it is characterized by the presence of small immature neuroepithelial cells.  It may follow an aggressive clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A76E3677-AE5C-F84A-E040-BB89AD435C45","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5022-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Pineocytoma","valueDescription":null,"ValueMeaning":{"publicId":"2578715","version":"1","preferredName":"Pineocytoma","longName":"2578715","preferredDefinition":"Pineocytoma (WHO grade II) is a slow growing tumor, more common in young adults. It is composed of small, uniform, mature cells resembling pineocytes with occasional large pineocytomatous rosettes.  It may show a wide range of divergent phenotypes, including neuronal, glial, melanocytic, photoreceptor and mesenchymal differentiation. Pineocytoma generally has a relatively favorable prognosis. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pineocytoma","conceptCode":"C6966","definition":"A WHO grade 1 slow growing tumor, more frequently affecting young adults. It is composed of small, uniform, mature cells resembling pineocytes with occasional large pineocytomatous rosettes. It may show a wide range of divergent phenotypes, including neuronal, glial, melanocytic, photoreceptor and mesenchymal differentiation. Pineocytoma generally has a relatively favorable prognosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0088-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5023-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Pleomorphic Xanthoastrocytoma","valueDescription":null,"ValueMeaning":{"publicId":"2578698","version":"1","preferredName":"Pleomorphic Xanthoastrocytoma","longName":"2578698","preferredDefinition":"Pleomorphic Xanthoastrocytoma is an astrocytic tumor with a relatively favorable prognosis (WHO grade II) and is typically encountered in children and young adults. It has a superficial location in the cerebral hemispheres and involvement of the meninges. Characteristic features include pleomorphic and lipidized cells expressing GFAP and often surrounded by a reticulin network as well as eosinophilic granular bodies. For lesions with significant mitotic activity (5 or more mitoses per 10 HPF) and/or with areas of necrosis, the designation \"pleomorphic xanthoastrocytoma with anaplastic features\" may be used. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleomorphic Xanthoastrocytoma","conceptCode":"C4323","definition":"A WHO grade 2 astrocytic tumor with a relatively favorable prognosis.  It is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies. It presents in the superficial cerebral hemispheres and involves the meninges. It typically affects children and young adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0077-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5024-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Rhabdomyosarcoma","valueDescription":null,"ValueMeaning":{"publicId":"4265253","version":"1","preferredName":"Rhabdomyosarcoma","longName":"4265253","preferredDefinition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomical sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rhabdomyosarcoma","conceptCode":"C3359","definition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4BB4-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5025-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Rosette-Forming Glioneuronal Tumor","valueDescription":null,"ValueMeaning":{"publicId":"14235577","version":"1","preferredName":"Rosette-Forming Glioneuronal Tumor","longName":"14235577v1.00","preferredDefinition":"A central nervous system neoplasm mostly occurring in the fourth ventricle region. It is characterized by the presence of neurocytes forming pseudorosettes and astrocytes which contain Rosenthal fibers. Cytologic atypia is minimal.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rosette-Forming Glioneuronal Tumor","conceptCode":"C129431","definition":"A central nervous system neoplasm mostly occurring in the fourth ventricle region. It is characterized by the presence of neurocytes forming pseudorosettes and astrocytes which contain Rosenthal fibers. Cytologic atypia is minimal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF7C0B-B1F4-71EF-E063-731AD00A2DF2","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5026-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Subependymal Giant Cell Astrocytoma","valueDescription":null,"ValueMeaning":{"publicId":"2573017","version":"1","preferredName":"Subependymal giant cell astrocytoma","longName":"2573017","preferredDefinition":"Subependymal Giant Cell Astrocytoma is a benign, slowly growing tumor (WHO grade I) typically arising in the wall of the lateral ventricles and composed of large ganglioid astrocytes. It is the most common CNS neoplasm in patients with Tuberous Sclerosis Complex and typically occurs during the first two decades of life. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subependymal Giant Cell Astrocytoma","conceptCode":"C3696","definition":"A benign, slowly growing tumor (WHO grade I) typically arising in the wall of the lateral ventricles and composed of large ganglioid astrocytes. It is the most common CNS neoplasm in patients with tuberous sclerosis complex and typically occurs during the first two decades of life. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA46-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5027-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Subependymoma","valueDescription":null,"ValueMeaning":{"publicId":"2578710","version":"1","preferredName":"Subependymoma","longName":"2578710","preferredDefinition":"Subependymoma (WHO grade I) is a benign, slow growing neoplasm which is typically attached to a ventricular wall. It is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic change. Some lesions have the histological features of both subependymoma and ependymoma. It is often detected incidentally and has a very favorable prognosis. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subependymoma","conceptCode":"C3795","definition":"A benign, slow growing neoplasm which is typically attached to a ventricular wall. It is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic change. Some lesions have the histological features of both subependymoma and ependymoma. It is often detected incidentally and has a very favorable prognosis. (Adapted from WHO.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0083-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5028-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Cribriform Neuroepithelial Tumor","valueDescription":null,"ValueMeaning":{"publicId":"14235607","version":"1","preferredName":"Cribriform Neuroepithelial Tumor","longName":"14235607v1.00","preferredDefinition":"A very rare, nonrhabdoid, intraventricular tumor with relatively favorable prognosis.  It is characterized by the presence of neuroepithelial cells forming cribriform patterns, trabeculae, epithelial membrane antigen immunopositivity on epithelial surfaces, and loss of nuclear INI 1 expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cribriform Neuroepithelial Tumor","conceptCode":"C121963","definition":"A very rare, nonrhabdoid, intraventricular tumor with relatively favorable prognosis.  It is characterized by the presence of neuroepithelial cells forming cribriform patterns, trabeculae, epithelial membrane antigen immunopositivity on epithelial surfaces, and loss of nuclear INI 1 expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1E7-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5029-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Atypical Teratoid/Rhabdoid Tumor-MYC","valueDescription":null,"ValueMeaning":{"publicId":"14235601","version":"1","preferredName":"ATRT-MYC","longName":"14235601v1.00","preferredDefinition":"Atypical teratoid/rhabdoid tumor characterized by overexpression of MYC genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Teratoid/Rhabdoid Tumor-MYC","conceptCode":"C200599","definition":"Atypical teratoid/rhabdoid tumor characterized by overexpression of MYC gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1D0-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-502A-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Atypical Teratoid/Rhabdoid Tumor-SHH","valueDescription":null,"ValueMeaning":{"publicId":"14235600","version":"1","preferredName":"ATRT-SHH","longName":"14235600v1.00","preferredDefinition":"Atypical teratoid/rhabdoid tumor characterized by overexpression of genes in the sonic hedgehog (SHH) pathway (GLI2, BOC, PTCHD2, and MYCN).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Teratoid/Rhabdoid Tumor-SHH","conceptCode":"C200598","definition":"Atypical teratoid/rhabdoid tumor characterized by overexpression of genes in the sonic hedgehog (SHH) pathway (GLI2, BOC, PTCHD2, and MYCN).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1CF-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-502B-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Atypical Teratoid/Rhabdoid Tumor-TYR","valueDescription":null,"ValueMeaning":{"publicId":"14235602","version":"1","preferredName":"ATRT-TYR","longName":"14235602v1.00","preferredDefinition":"Atypical teratoid/rhabdoid tumor characterized by overexpression of melanosomal genes (TYR, TYRP, MITF, and OTX2).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Teratoid/Rhabdoid Tumor-TYR","conceptCode":"C200600","definition":"Atypical teratoid/rhabdoid tumor characterized by overexpression of melanosomal genes (TYR, TYRP, MITF, and OTX2).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1D1-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-502C-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Dysplastic Cerebellar Gangliocytoma","valueDescription":null,"ValueMeaning":{"publicId":"3249589","version":"1","preferredName":"Dysplastic Cerebellar Gangliocytoma","longName":"3249589","preferredDefinition":"Dysplastic Gangliocytoma of the Cerebellum (WHO grade I), also called Lhermitte-Duclos disease, is a benign cerebellar mass, which occurs in young adults and is composed of dysplastic ganglion cells.  It is the major CNS manifestation of Cowden Disease, an autosomal dominant condition that causes a variety of hamartomas and neoplasms.(Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysplastic Cerebellar Gangliocytoma","conceptCode":"C8419","definition":"A benign, WHO grade I cerebellar mass, which occurs in young adults and is composed of dysplastic ganglion cells.  It is the major CNS manifestation of Cowden disease, an autosomal dominant condition that causes a variety of hamartomas and neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D99025-BF63-DBB4-E040-BB89AD434418","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-502D-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Dural Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","valueDescription":null,"ValueMeaning":{"publicId":"14235576","version":"1","preferredName":"Dural Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","longName":"14235576v1.00","preferredDefinition":"A rare, primary marginal zone lymphoma of mucosa-associated lymphoid tissue that arises from the meningeal dura.  The majority of cases have been described in middle aged women.  Radiologically, the lymphomatous dural infiltration mimics meningioma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dural Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","conceptCode":"C95991","definition":"A rare, primary marginal zone lymphoma of mucosa-associated lymphoid tissue that arises from the meningeal dura.  The majority of cases have been described in middle aged women.  Radiologically, the lymphomatous dural infiltration mimics meningioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF7926-1F61-717F-E063-731AD00A089A","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-502E-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Medulloblastoma, Non-WNT/Non-SHH, Group 3","valueDescription":null,"ValueMeaning":{"publicId":"14235597","version":"1","preferredName":"Medulloblastoma, Non-WNT/Non-SHH, Group 3","longName":"14235597v1.00","preferredDefinition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. MYC amplifications may be present. TP53 mutations are absent. Patients in this group are usually young children. The overall survival is the worst among all the molecular groups.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma, Non-WNT/Non-SHH, Group 3","conceptCode":"C129445","definition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. MYC amplifications may be present. TP53 mutations are absent. Patients in this group are usually young children. The overall survival is the worst among all the molecular groups.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1E0-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-502F-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Medulloblastoma, Non-WNT/Non-SHH, Group 4","valueDescription":null,"ValueMeaning":{"publicId":"14235598","version":"1","preferredName":"Medulloblastoma, Non-WNT/Non-SHH, Group 4","longName":"14235598v1.00","preferredDefinition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. MYC amplifications are absent. TP53 mutations are absent. Chromosome 17 abnormalities may be present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma, Non-WNT/Non-SHH, Group 4","conceptCode":"C129446","definition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. MYC amplifications are absent. TP53 mutations are absent. Chromosome 17 abnormalities may be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1E1-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5030-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Pituitary Gland Blastoma","valueDescription":null,"ValueMeaning":{"publicId":"13628708","version":"1","preferredName":"Pituitary Gland Blastoma","longName":"13628708v1.00","preferredDefinition":"A rare developmental early childhood neoplasm, arising within the fetal anterior pituitary. It is associated with DICER1 mutations. Patients present with features of Cushing disease, with elevated blood ACTH levels and hypercortisolism. Ophthalmoplegia is a frequent symptom. The overall prognosis is poor. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pituitary Gland Blastoma","conceptCode":"C155304","definition":"A rare developmental early childhood neoplasm, arising within the fetal anterior pituitary. It is associated with DICER1 mutations. Patients present with features of Cushing disease, with elevated blood ACTH levels and hypercortisolism. Ophthalmoplegia is a frequent symptom. The overall prognosis is poor. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC5C665A-6935-7E5E-E053-731AD00AF906","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-23","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5031-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","valueDescription":null,"ValueMeaning":{"publicId":"3928506","version":"1","preferredName":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","longName":"3928506","preferredDefinition":"A diffuse large B-cell lymphoma arising from the central nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","conceptCode":"C71720","definition":"A diffuse large B-cell lymphoma arising from the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-33C9-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5032-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Rosai-Dorfman-Destombes Disease","valueDescription":null,"ValueMeaning":{"publicId":"3211424","version":"1","preferredName":"Sinus Histiocytosis with Massive Lymphadenopathy","longName":"3211424","preferredDefinition":"A rare non-neoplastic disorder of unknown etiology characterized by distention of the lymph node sinuses and sinusoidal histiocytic infiltration. The histiocytes characteristically contain ingested lymphocytes. It is usually manifested with cervical lymphadenopathy, fever, leukocytosis, and hypergammaglobulinemia. . It can affect extranodal sites, including the skin, bones, and the respiratory tract. It usually regresses spontaneously.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rosai-Dorfman-Destombes Disease","conceptCode":"C36075","definition":"A rare histiocytic disorder of unknown etiology, characterized by distention of the lymph node sinuses and sinusoidal histiocytic infiltration. The histiocytes characteristically contain ingested lymphocytes and are S100 and CD68 positive, and CD1a negative. Patients present with cervical lymphadenopathy, fever, leukocytosis, and hypergammaglobulinemia. It can affect extranodal sites, including skin, bones, and the respiratory tract. It occurs in isolation or may be associated with autoimmune disorders or malignancies. Mutations in NRAS, KRAS, MAP2K1, and ARAF genes have been identified in affected tissues, suggesting a clonal origin in some cases. It is a self-limited disorder, although some patients may have a poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FBD3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5033-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Astroblastoma, MN1-Altered","valueDescription":null,"ValueMeaning":{"publicId":"2578712","version":"1","preferredName":"Astroblastoma","longName":"2578712","preferredDefinition":"Astroblastoma is a rare glial neoplasm more commonly found in young adults. It is characterized by tumor cells with characteristics suggestive of an astrocytic origin (positive for GFAP), arranged perivascularly. The cells have broad, non-tapering processes radiating towards a central blood vessel. The biologic behavior of astroblastomas is variable, so no WHO grade has been established, yet. (Adapted from WHO.) NCIPDQ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Astroblastoma, MN1-Altered","conceptCode":"C4324","definition":"A rare glial neoplasm characterized by structural rearrangements of the MN1 gene at chromosome band 22q12.1. It is usually found in the cerebral hemispheres of young adults and children and predominantly affects females. Morphologically, it consists of elongated glial cells with abundant eosinophilic cytoplasm and GFAP-positive processes, arranged perivascularly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0085-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5034-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Atypical Choroid Plexus Papilloma","valueDescription":null,"ValueMeaning":{"publicId":"13628846","version":"1","preferredName":"Atypical Choroid Plexus Papilloma","longName":"13628846v1.00","preferredDefinition":"A choroid plexus papilloma characterized by increased mitotic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Choroid Plexus Papilloma","conceptCode":"C53686","definition":"A choroid plexus papilloma characterized by increased mitotic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC5EECF7-BF2E-7357-E053-731AD00AC348","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-23","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5035-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Central Neurocytoma","valueDescription":null,"ValueMeaning":{"publicId":"2578719","version":"1","preferredName":"Central neurocytoma","longName":"2578719","preferredDefinition":"Central Neurocytoma is an intraventricular neuronal neoplasm composed of uniform round cells with neuronal differentiation. It is typically located in the lateral ventricles in the region of the foramen of Monro.  It generally affects young adults and has a favorable prognosis. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Neurocytoma","conceptCode":"C3791","definition":"An intraventricular neuronal neoplasm composed of uniform round cells with neuronal differentiation. It is typically located in the lateral ventricles in the region of the foramen of Monro. It generally affects young adults and has a favorable prognosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-008C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5036-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Diffuse Low Grade Glioma, MAPK Pathway-Altered","valueDescription":null,"ValueMeaning":{"publicId":"14235585","version":"1","preferredName":"Diffuse Low Grade Glioma, MAPK Pathway-Altered","longName":"14235585v1.00","preferredDefinition":"A rare, low-grade diffuse glioma with morphological features of astrocytoma or oligodendroglioma, generally affecting children. It is characterized by a gene alteration that results in a MAPK pathway abnormality. The genetic abnormalities are typically a BRAF p.V600E substitution mutation, mutations or fusions involving the FGFR1 gene and internal tandem duplication (ITD) of the sequences of FGFR1 gene encoding the tyrosine kinase domain (TKD). The tumor is IDH-wildtype and does not have a homozygous deletion of CDKN2A gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Low Grade Glioma, MAPK Pathway-Altered","conceptCode":"C185218","definition":"A rare, low-grade diffuse glioma with morphological features of astrocytoma or oligodendroglioma, generally affecting children. It is characterized by a gene alteration that results in a MAPK pathway abnormality. The genetic abnormalities are typically a BRAF p.V600E substitution mutation, mutations or fusions involving the FGFR1 gene and internal tandem duplication (ITD) of the sequences of FGFR1 gene encoding the tyrosine kinase domain (TKD). The tumor is IDH-wildtype and does not have a homozygous deletion of CDKN2A gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1D4-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5037-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Diffuse Pediatric-Type High Grade Glioma, H3-Wildtype and IDH-Wildtype","valueDescription":null,"ValueMeaning":{"publicId":"14235245","version":"1","preferredName":"Diffuse Pediatric-Type High Grade Glioma, H3-Wildtype and IDH-Wildtype","longName":"14235245v1.00","preferredDefinition":"An aggressive, WHO grade 4 diffuse brain glioma usually affecting children, adolescents, or young adults. It is characterized by the absence of histone H3, IDH1, and IDH2 mutations. It includes the following subtypes, based on DNA methylation profiles: diffuse pediatric-type high grade glioma RTK1, diffuse pediatric-type high grade glioma RTK2, and diffuse pediatric-type high grade glioma MYCN.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Pediatric-Type High Grade Glioma, H3-Wildtype and IDH-Wildtype","conceptCode":"C185467","definition":"An aggressive, WHO grade 4 diffuse brain glioma usually affecting children, adolescents, or young adults. It is characterized by the absence of histone H3, IDH1, and IDH2 mutations. It includes the following subtypes, based on DNA methylation profiles: diffuse pediatric-type high grade glioma RTK1, diffuse pediatric-type high grade glioma RTK2, and diffuse pediatric-type high grade glioma MYCN.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CBA8C7-0CA2-4A47-E063-731AD00A98B9","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"LISU","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5038-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"High Grade Astrocytoma with Piloid Features","valueDescription":null,"ValueMeaning":{"publicId":"14235242","version":"1","preferredName":"High Grade Astrocytoma with Piloid Features","longName":"14235242v1.00","preferredDefinition":"An astrocytoma characterized by high-grade piloid and/or glioblastoma-like histological features. It may occur anywhere in the central nervous system but most often arises in the posterior fossa. Alterations in the following three pathways are responsible for the pathogenesis of this tumor: MAPK pathway, retinoblastoma tumor suppressor protein cell-cycle pathway, and telomere maintenance pathway.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade Astrocytoma with Piloid Features","conceptCode":"C185879","definition":"An astrocytoma characterized by high-grade piloid and/or glioblastoma-like histological features. It may occur anywhere in the central nervous system but most often arises in the posterior fossa. Alterations in the following three pathways are responsible for the pathogenesis of this tumor: MAPK pathway, retinoblastoma tumor suppressor protein cell-cycle pathway, and telomere maintenance pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CBA8C7-0C9F-4A47-E063-731AD00A98B9","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"LISU","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5039-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Infant-Type Hemispheric Glioma","valueDescription":null,"ValueMeaning":{"publicId":"14235246","version":"1","preferredName":"Infant-Type Hemispheric Glioma","longName":"14235246v1.00","preferredDefinition":"A high-grade cellular astrocytoma that arises in the cerebral hemisphere and occurs in early childhood. It is characterized by receptor tyrosine kinase fusions in the NTRK family, ROS1, ALK, or MET genes. It includes the following subtypes: infant-type hemispheric glioma, NTRK-altered, infant-type hemispheric glioma, ROS1-altered, infant-type hemispheric glioma, ALK-altered, and infant-type hemispheric glioma, MET-altered.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infant-Type Hemispheric Glioma","conceptCode":"C185471","definition":"A high-grade cellular astrocytoma that arises in the cerebral hemisphere and occurs in early childhood. It is characterized by receptor tyrosine kinase fusions in the NTRK family, ROS1, ALK, or MET genes. It includes the following subtypes: infant-type hemispheric glioma, NTRK-altered, infant-type hemispheric glioma, ROS1-altered, infant-type hemispheric glioma, ALK-altered, and infant-type hemispheric glioma, MET-altered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CBA8C7-0CA3-4A47-E063-731AD00A98B9","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"LISU","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-503A-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Intracranial Mesenchymal Tumor, FET-CREB Fusion-Positive","valueDescription":null,"ValueMeaning":{"publicId":"14236697","version":"1","preferredName":"Intracranial Mesenchymal Tumor, FET-CREB Fusion-Positive","longName":"14236697v1.00","preferredDefinition":"A provisional entity that refers to a group of neoplasms with a broad morphological spectrum, characterized by fusion of a FET family gene (usually EWSR1 and rarely FUS) with a member of the CREB family of transcription factors (CREB1, ATF1, or CREM). It includes entities previously termed intracranial angiomatoid fibrous histiocytoma or intracranial myxoid mesenchymal tumor. It is usually located in the supratentorial brain and mostly affects children and young adults. There is a spectrum of clinical behaviors ranging from slowly growing tumors to rapid recurrences, and rarely metastases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intracranial Mesenchymal Tumor, FET-CREB Fusion-Positive","conceptCode":"C186614","definition":"A provisional entity that refers to a group of neoplasms with a broad morphological spectrum, characterized by fusion of a FET family gene (usually EWSR1 and rarely FUS) with a member of the CREB family of transcription factors (CREB1, ATF1, or CREM). It includes entities previously termed intracranial angiomatoid fibrous histiocytoma or intracranial myxoid mesenchymal tumor. It is usually located in the supratentorial brain and mostly affects children and young adults. There is a spectrum of clinical behaviors ranging from slowly growing tumors to rapid recurrences, and rarely metastases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01DF4B35-7F7A-6E52-E063-731AD00A01F2","latestVersionIndicator":"Yes","beginDate":"2023-08-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-01","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-503B-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Mesenchymal Chondrosarcoma","valueDescription":null,"ValueMeaning":{"publicId":"3179360","version":"1","preferredName":"Mesenchymal Chondrosarcoma","longName":"3179360","preferredDefinition":"A rare morphologic variant of chondrosarcoma. It is characterized by the presence of malignant small round cells, biphasic growth pattern, and well differentiated hyaline cartilage. Clinical presentation includes pain and swelling. The clinical course is aggressive, with local recurrences and distant metastases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesenchymal Chondrosarcoma","conceptCode":"C3737","definition":"A morphologic variant of chondrosarcoma arising from bone and soft tissue. It is characterized by the presence of malignant small round cells, biphasic growth pattern, and well differentiated hyaline cartilage. Clinical presentation includes pain and swelling. The clinical course is aggressive, with local recurrences and distant metastases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-85EA-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-503C-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Multinodular and Vacuolated Neuronal Tumor","valueDescription":null,"ValueMeaning":{"publicId":"14235580","version":"1","preferredName":"Multinodular and Vacuolated Neuronal Tumor","longName":"14235580v1.00","preferredDefinition":"A low-grade tumor affecting the cerebral hemispheres. It is composed of cells with glial and/or neuronal differentiation forming multiple nodules with prominent vacuolation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multinodular and Vacuolated Neuronal Tumor","conceptCode":"C129427","definition":"A low-grade tumor affecting the cerebral hemispheres. It is composed of cells with glial and/or neuronal differentiation forming multiple nodules with prominent vacuolation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF7C0B-B1F7-71EF-E063-731AD00A2DF2","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-503D-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Myxopapillary Ependymoma","valueDescription":null,"ValueMeaning":{"publicId":"3249044","version":"1","preferredName":"Myxopapillary Ependymoma","longName":"3249044","preferredDefinition":"Myxopapillary Ependymomas (WHO grade I) are slow growing gliomas which generally occur in young adults and arise almost exclusively in the conus-cauda-filum terminale region. It generally has a favorable prognosis and is characterized histologically by tumor cells arranged in a papillary manner around vascularized mucoid stromal cores. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myxopapillary Ependymoma","conceptCode":"C3697","definition":"A slow growing, WHO grade I glioma which generally occurs in young adults.  It arises almost exclusively in the conus medullaris, cauda equina, and filum terminale of the spinal cord. It generally has a favorable prognosis and is characterized histologically by tumor cells arranged in a papillary manner around vascularized mucoid stromal cores. (Adapted from WHO).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA5E9E-17BC-D7DA-E040-BB89AD432E47","latestVersionIndicator":"Yes","beginDate":"2011-06-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-28","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-503E-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Polymorphous Low Grade Neuroepithelial Tumor of the Young","valueDescription":null,"ValueMeaning":{"publicId":"14235584","version":"1","preferredName":"Polymorphous Low Grade Neuroepithelial Tumor of the Young","longName":"14235584v1.00","preferredDefinition":"A low-grade cerebral tumor associated with seizures and in many cases refractory epilepsy. It usually occurs in the second and third decades of life. It is characterized by the presence of oligodendroglioma-like components. It may also contain astrocytic components. MAPK pathway-activating genetic alterations play a role in the development of this tumor. Causative gene alterations include mutations resulting in the expression of BRAF p.V600E and gene fusions involving FGFR2 or FGFR3 genes. IDH gene mutations and 1p/19q codeletion are not present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymorphous Low Grade Neuroepithelial Tumor of the Young","conceptCode":"C180378","definition":"A low-grade cerebral tumor associated with seizures and in many cases refractory epilepsy. It usually occurs in the second and third decades of life. It is characterized by the presence of oligodendroglioma-like components. It may also contain astrocytic components. MAPK pathway-activating genetic alterations play a role in the development of this tumor. Causative gene alterations include mutations resulting in the expression of BRAF p.V600E and gene fusions involving FGFR2 or FGFR3 genes. IDH gene mutations and 1p/19q codeletion are not present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1D3-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-503F-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Primary Intracranial Sarcoma, DICER1-Mutant","valueDescription":null,"ValueMeaning":{"publicId":"14235571","version":"1","preferredName":"Primary Intracranial Sarcoma, DICER1-Mutant","longName":"14235571v1.00","preferredDefinition":"A primary intracranial sarcoma composed of malignant pleomorphic or spindle neoplastic cells typically demonstrating myogenic and/or chondroid differentiation. Cytoplasmic eosinophilic globules and myxoid stroma formation are usually present. It is associated with mutations in the DICER1 gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Intracranial Sarcoma, DICER1-Mutant","conceptCode":"C186610","definition":"A primary intracranial sarcoma composed of malignant pleomorphic or spindle neoplastic cells typically demonstrating myogenic and/or chondroid differentiation. Cytoplasmic eosinophilic globules and myxoid stroma formation are usually present. It is associated with mutations in the DICER1 gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF7926-1F5C-717F-E063-731AD00A089A","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5040-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Solitary Fibrous Tumor","valueDescription":null,"ValueMeaning":{"publicId":"3249525","version":"1","preferredName":"Solitary Fibrous Tumor","longName":"3249525","preferredDefinition":"A localized neoplasm of probable fibroblastic derivation. It is characterized by the presence of round to spindle-shaped cells, hylanized stroma formation, thin-walled branching blood vessels, and thin bands of collagen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solitary Fibrous Tumor","conceptCode":"C7634","definition":"A localized neoplasm of probable fibroblastic derivation. It is characterized by the presence of round to spindle-shaped cells, hylanized stroma formation, thin-walled branching blood vessels, and thin bands of collagen.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D8A436-0652-647C-E040-BB89AD435D86","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5041-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Supratentorial Ependymoma YAP1 Fusion-Positive","valueDescription":null,"ValueMeaning":{"publicId":"14235590","version":"1","preferredName":"Supratentorial Ependymoma YAP1 Fusion-Positive","longName":"14235590v1.00","preferredDefinition":"An uncommon circumscribed ependymoma that arises from the supratentorial region of the brain. It affects young children and is characterized by the presence of a fusion gene involving YAP1 gene. Available data indicate that it has a favorable prognosis as compared to other supratentorial ependymomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Supratentorial Ependymoma YAP1 Fusion-Positive","conceptCode":"C186351","definition":"An uncommon circumscribed ependymoma that arises from the supratentorial region of the brain. It affects young children and is characterized by the presence of a fusion gene involving YAP1 gene. Available data indicate that it has a favorable prognosis as compared to other supratentorial ependymomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1D9-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5042-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Supratentorial Ependymoma ZFTA Fusion-Positive","valueDescription":null,"ValueMeaning":{"publicId":"14235589","version":"1","preferredName":"Supratentorial Ependymoma ZFTA Fusion-Positive","longName":"14235589v1.00","preferredDefinition":"A circumscribed ependymoma that arises from the supratentorial region of the brain. It is characterized by the presence of a fusion gene involving ZFTA gene. Available data indicate that it has the poorest prognosis of all supratentorial ependymomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Supratentorial Ependymoma ZFTA Fusion-Positive","conceptCode":"C186350","definition":"A circumscribed ependymoma that arises from the supratentorial region of the brain. It is characterized by the presence of a fusion gene involving ZFTA gene. Available data indicate that it has the poorest prognosis of all supratentorial ependymomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1D8-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5043-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Central Nervous System Germinoma","valueDescription":null,"ValueMeaning":{"publicId":"4722577","version":"1","preferredName":"Central Nervous System Germinoma","longName":"4722577","preferredDefinition":"A malignant germ cell tumor arising from the central nervous system.  It is composed of uniform cells resembling primitive germ cells.  These cells have large, vesicular nuclei, prominent nucleoli and a clear, glycogen-rich cytoplasm.  Additional features are lymphoid or lymphoplasmacytic infiltrates and, less frequently, scattered syncytiotrophoblastic giant cells.  (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Germinoma","conceptCode":"C7009","definition":"A malignant germ cell tumor arising from the central nervous system.  It is composed of uniform cells resembling primitive germ cells.  These cells have large, vesicular nuclei, prominent nucleoli and a clear, glycogen-rich cytoplasm.  Additional features are lymphoid or lymphoplasmacytic infiltrates and, less frequently, scattered syncytiotrophoblastic giant cells.  (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F899F68-B716-D077-E050-BB89AD434EE9","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5044-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Central Nervous System Neuroblastoma, FOXR2-Activated","valueDescription":null,"ValueMeaning":{"publicId":"14235605","version":"1","preferredName":"Central Nervous System Neuroblastoma, FOXR2-Activated","longName":"14235605v1.00","preferredDefinition":"A rare central nervous system neoplasm with neuroblastic and/or neuronal differentiation. It is characterized by the presence of structural rearrangements of FOXR2 gene that result in the activation of the transcription factor FOXR2.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Neuroblastoma, FOXR2-Activated","conceptCode":"C186547","definition":"A rare central nervous system neoplasm with neuroblastic and/or neuronal differentiation. It is characterized by the presence of structural rearrangements of FOXR2 gene that result in the activation of the transcription factor FOXR2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1E5-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5045-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Mouse Desmoplastic Infantile Astrocytoma / Ganglioglioma","valueDescription":null,"ValueMeaning":{"publicId":"14737546","version":"1","preferredName":"Mouse Desmoplastic Infantile Astrocytoma / Ganglioglioma","longName":"14737546v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mouse Desmoplastic Infantile Astrocytoma / Ganglioglioma","conceptCode":"C21969","definition":"Desmoplastic infantile astrocytoma / ganglioglioma occurring in a mouse.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"102EC34E-4FFE-3B3A-E063-731AD00ACA0E","latestVersionIndicator":"Yes","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5046-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Spinal Cord Ependymoma, MYCN Amplified","valueDescription":null,"ValueMeaning":{"publicId":"14235595","version":"1","preferredName":"Spinal Cord Ependymoma, MYCN Amplified","longName":"14235595v1.00","preferredDefinition":"A rare, aggressive ependymoma that arises from the spinal cord. It displays microvascular proliferation, necrosis, and high mitotic rate. It is characterized by high-level MYCN amplification. Cytogenetic abnormalities include loss of chromosome 10 and focal losses on chromosome 11q. The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spinal Cord Ependymoma, MYCN Amplified","conceptCode":"C186494","definition":"A rare, aggressive ependymoma that arises from the spinal cord. It displays microvascular proliferation, necrosis, and high mitotic rate. It is characterized by high-level MYCN amplification. Cytogenetic abnormalities include loss of chromosome 10 and focal losses on chromosome 11q. The prognosis is poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1DE-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102EC34E-5047-3B3A-E063-731AD00ACA0E","beginDate":"2024-01-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Posterior fossa ependymoma, group PFA","valueDescription":null,"ValueMeaning":{"publicId":"14235592","version":"1","preferredName":"Posterior Fossa Ependymoma, Group A (PFA)","longName":"14235592v1.00","preferredDefinition":"A circumscribed ependymoma that arises in the posterior fossa with characteristic DNA methylation patterns, including CpG island hypermethylation, global DNA hypomethylation, reduction of nuclear H3 p.K28me3 (K27me3) expression, and EZHIP  overexpression. It usually occurs in children younger than five years. PFA ependymomas have a worst prognosis compared to PFB ependymomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Posterior Fossa Ependymoma, Group A (PFA)","conceptCode":"C186450","definition":"A circumscribed ependymoma that arises in the posterior fossa with characteristic DNA methylation patterns, including CpG island hypermethylation, global DNA hypomethylation, reduction of nuclear H3 p.K28me3 (K27me3) expression, and EZHIP  overexpression. It usually occurs in children younger than five years. PFA ependymomas have a worst prognosis compared to PFB ependymomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1DB-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1046A73A-7D28-60C1-E063-731AD00A0C8D","beginDate":"2024-01-31","endDate":null,"createdBy":"COLBERTM","dateCreated":"2024-01-31","modifiedBy":"COLBERTM","dateModified":"2024-01-31","deletedIndicator":"No"},{"value":"Posterior fossa ependymoma, group PFB","valueDescription":null,"ValueMeaning":{"publicId":"14235593","version":"1","preferredName":"Posterior Fossa Ependymoma, Group B (PFB)","longName":"14235593v1.00","preferredDefinition":"A circumscribed ependymoma that arises in the posterior fossa with characteristic DNA methylation patterns including retention of nuclear H3 p.K28me3 (K27me3) expression, absence of CpG island hypermethylation, absence of global DNA hypomethylation, and absence of EZHIP overexpression. Widespread cytogenetic abnormalities are present. Frequent chromosomal aberrations include loss of 22q, monosomy 6, and trisomy 18. It occurs in children older than five years and adults and has a relatively good prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Posterior Fossa Ependymoma, Group B (PFB)","conceptCode":"C186451","definition":"A circumscribed ependymoma that arises in the posterior fossa with characteristic DNA methylation patterns including retention of nuclear H3 p.K28me3 (K27me3) expression, absence of CpG island hypermethylation, absence of global DNA hypomethylation, and absence of EZHIP overexpression. Widespread cytogenetic abnormalities are present. Frequent chromosomal aberrations include loss of 22q, monosomy 6, and trisomy 18. It occurs in children older than five years and adults and has a relatively good prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1DC-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1046A73A-7D29-60C1-E063-731AD00A0C8D","beginDate":"2024-01-31","endDate":null,"createdBy":"COLBERTM","dateCreated":"2024-01-31","modifiedBy":"COLBERTM","dateModified":"2024-01-31","deletedIndicator":"No"},{"value":"Pituitary adenoma/PitNET","valueDescription":null,"ValueMeaning":{"publicId":"13628764","version":"1","preferredName":"Pituitary Neuroendocrine Tumor","longName":"13628764v1.00","preferredDefinition":"A well-differentiated neuroendocrine neoplasm that arises from the adenohypophysial cells of the anterior lobe of the pituitary gland. The tumor can be hormonally functioning or not. It has a low frequency of metastatic spread. When metastatic, the term metastatic pituitary neuroendocrine tumor is endorsed instead of pituitary carcinoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pituitary Neuroendocrine Tumor","conceptCode":"C3329","definition":"A well-differentiated neuroendocrine neoplasm that arises from the adenohypophysial cells of the anterior lobe of the pituitary gland. The tumor can be hormonally functioning or not. It has a low frequency of metastatic spread. When metastatic, the term metastatic pituitary neuroendocrine tumor is endorsed instead of pituitary carcinoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC5D8F24-E8A9-379A-E053-731AD00A9875","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-23","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1046A73A-7D2A-60C1-E063-731AD00A0C8D","beginDate":"2024-01-31","endDate":null,"createdBy":"COLBERTM","dateCreated":"2024-01-31","modifiedBy":"COLBERTM","dateModified":"2024-01-31","deletedIndicator":"No"},{"value":"Medulloblastoma, SHH-activated andTP53-mutant","valueDescription":null,"ValueMeaning":{"publicId":"13628698","version":"1","preferredName":"Medulloblastoma, SHH-Activated, TP53-Mutant","longName":"13628698v1.00","preferredDefinition":"Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the presence of TP53 mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma, SHH-Activated, TP53-Mutant","conceptCode":"C129442","definition":"Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the presence of TP53 mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC5C17D9-EAE3-7245-E053-731AD00A5A6D","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-23","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"106B4713-9383-4C61-E063-731AD00A0C0A","beginDate":"2024-02-02","endDate":null,"createdBy":"COLBERTM","dateCreated":"2024-02-02","modifiedBy":"COLBERTM","dateModified":"2024-02-02","deletedIndicator":"No"},{"value":"Medulloblastoma, SHH-activated andTP53-wildtype","valueDescription":null,"ValueMeaning":{"publicId":"14235596","version":"1","preferredName":"Medulloblastoma, SHH-Activated, TP53-Wildtype","longName":"14235596v1.00","preferredDefinition":"Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the absence of TP53 mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma, SHH-Activated, TP53-Wildtype","conceptCode":"C129443","definition":"Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the absence of TP53 mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF8277-A1DF-72B0-E063-731AD00A20FA","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"106B4713-9384-4C61-E063-731AD00A0C0A","beginDate":"2024-02-02","endDate":null,"createdBy":"COLBERTM","dateCreated":"2024-02-02","modifiedBy":"COLBERTM","dateModified":"2024-02-02","deletedIndicator":"No"},{"value":"Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted","valueDescription":null,"ValueMeaning":{"publicId":"5698556","version":"1","preferredName":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","longName":"5698556","preferredDefinition":"An oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","conceptCode":"C129318","definition":"An oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B1F7-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"106B4713-9385-4C61-E063-731AD00A0C0A","beginDate":"2024-02-02","endDate":null,"createdBy":"COLBERTM","dateCreated":"2024-02-02","modifiedBy":"COLBERTM","dateModified":"2024-02-02","deletedIndicator":"No"},{"value":"Supratentorial ependymoma, NOS or NEC","valueDescription":null,"ValueMeaning":{"publicId":"14741353","version":"1","preferredName":"Childhood Supratentorial Ependymoma, Not Otherwise Specified","longName":"14741353v1.00","preferredDefinition":"An ependymoma, not otherwise specified that arises from the supratentorial region of the brain and occurs during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Supratentorial Ependymoma, Not Otherwise Specified","conceptCode":"C9043","definition":"An ependymoma, not otherwise specified that arises from the supratentorial region of the brain and occurs during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"106B4DC0-95FE-4D7A-E063-731AD00A0348","latestVersionIndicator":"Yes","beginDate":"2024-02-02","endDate":null,"createdBy":"COLBERTM","dateCreated":"2024-02-02","modifiedBy":"COLBERTM","dateModified":"2024-02-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"106B4DC0-95FF-4D7A-E063-731AD00A0348","beginDate":"2024-02-02","endDate":null,"createdBy":"COLBERTM","dateCreated":"2024-02-02","modifiedBy":"COLBERTM","dateModified":"2024-02-02","deletedIndicator":"No"},{"value":"ATRT, NOS or NEC","valueDescription":null,"ValueMeaning":{"publicId":"4722554","version":"1","preferredName":"Atypical Teratoid/Rhabdoid Tumor","longName":"4722554","preferredDefinition":"An aggressive malignant embryonal neoplasm arising from the central nervous system.  It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.  It may be associated with loss of chromosome 22.  The vast majority of cases occur in childhood.  Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Teratoid/Rhabdoid Tumor","conceptCode":"C6906","definition":"An aggressive malignant embryonal neoplasm arising from the central nervous system. It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm. Mutations of the SMARCB1 gene or very rarely SMARCA4 (BRG1) gene are present. The vast majority of cases occur in childhood. Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B6B7-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B24-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Chordoma (including poorly differentiated chordoma)","valueDescription":null,"ValueMeaning":{"publicId":"3179237","version":"1","preferredName":"Chordoma","longName":"3179237","preferredDefinition":"A malignant bone tumor arising from the remnants of the fetal notochord. Although it can occur at all ages, it is more frequently seen in middle-aged adults. Most frequent sites of involvement are: sacrococcygeal area, spheno-occipital area, and the cervico-thoraco-lumbar spine. Microscopically, chordomas are composed of cells that form cords and lobules, separated by mucoid intercellular tissue. Some of the cells are large (physaliphorous) and have vacuolated cytoplasm and prominent vesicular nuclei. Other tumor cells are small with small nuclei without visible nucleoli. Chordomas tend to recur and may metastasize. The most common sites of metastasis are skin and bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chordoma","conceptCode":"C2947","definition":"A malignant bone tumor arising from the remnants of the fetal notochord. Although it can occur at all ages, it is more frequently seen in middle-aged adults. The most frequent sites of involvement are the sacrococcygeal area, spheno-occipital area, and cervico-thoraco-lumbar spine. Chordomas tend to recur and may metastasize. The most common sites of metastasis are lung, bone, lymph nodes, and subcutaneous tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9881C41C-CDC6-C63B-E040-BB89AD437873","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-28","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B25-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"CNS embryonal tumor, NOS or NEC","valueDescription":null,"ValueMeaning":{"publicId":"14741367","version":"1","preferredName":"Central Nervous System Embryonal Tumor, Not Otherwise Specified","longName":"14741367v1.00","preferredDefinition":"A term that refers to central nervous system embryonal tumors which are not fully characterized.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Embryonal Tumor, Not Otherwise Specified","conceptCode":"C5398","definition":"A term that refers to central nervous system embryonal tumors which are not fully characterized.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A31AAE-9B1C-6E06-E063-731AD00A6D2B","latestVersionIndicator":"Yes","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B26-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"CNS Non-Germinomatous Germ Cell Tumor","valueDescription":null,"ValueMeaning":{"publicId":"14741368","version":"1","preferredName":"Childhood Nongerminomatous Germ Cell Tumor","longName":"14741368v1.00","preferredDefinition":"A nongerminomatous germ cell tumor occurring in children.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Nongerminomatous Germ Cell Tumor","conceptCode":"C123841","definition":"A nongerminomatous germ cell tumor occurring in children.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A31AAE-9B1D-6E06-E063-731AD00A6D2B","latestVersionIndicator":"Yes","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B27-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"CNS Sarcoma, NOS or NEC","valueDescription":null,"ValueMeaning":{"publicId":"14235234","version":"1","preferredName":"Central Nervous System Sarcoma","longName":"14235234v1.00","preferredDefinition":"A sarcoma that arises from the central nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Sarcoma","conceptCode":"C5153","definition":"A sarcoma that arises from the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CADF05-E716-2BCD-E063-731AD00A4231","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"LISU","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B28-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Desmoplastic myxoid tumor of the pineal region,SMARCB1-mutant","valueDescription":null,"ValueMeaning":{"publicId":"14235558","version":"1","preferredName":"Desmoplastic Myxoid Tumor of the Pineal Region, SMARCB1-Mutant","longName":"14235558v1.00","preferredDefinition":"A SMARCB1-deficient tumor of the brain arising in the pineal region. It is characterized by the presence of spindled and epithelioid cells with low-grade morphology that are embedded in a desmoplastic stroma alternating with various extents of loose myxoid matrix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desmoplastic Myxoid Tumor of the Pineal Region, SMARCB1-Mutant","conceptCode":"C178507","definition":"A SMARCB1-deficient tumor of the brain arising in the pineal region. It is characterized by the presence of spindled and epithelioid cells with low-grade morphology that are embedded in a desmoplastic stroma alternating with various extents of loose myxoid matrix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF6B9B-8490-703C-E063-731AD00A6B0E","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B29-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Embryonal tumor with multilayered rosettes, C19MC altered","valueDescription":null,"ValueMeaning":{"publicId":"14741369","version":"1","preferredName":"Childhood Embryonal Tumor with Multilayered Rosettes, C19MC-Altered","longName":"14741369v1.00","preferredDefinition":"An embryonal tumor with multilayered rosettes, C19MC-altered that occurs during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Embryonal Tumor with Multilayered Rosettes, C19MC-Altered","conceptCode":"C115203","definition":"An embryonal tumor with multilayered rosettes, C19MC-altered that occurs during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A31AAE-9B1E-6E06-E063-731AD00A6D2B","latestVersionIndicator":"Yes","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B2A-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Embryonal tumor with multilayered rosettes, NOS","valueDescription":null,"ValueMeaning":{"publicId":"10497046","version":"1","preferredName":"Embryonal Tumor with Multilayered Rosettes","longName":"10497046v1.00","preferredDefinition":"A central nervous system embryonal tumor characterized by the presence of multilayered rosette formation and typically the presence of amplification of the C19MC region on chromosome 19 (19q13.42) or rarely a DICER1 mutation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Embryonal Tumor with Multilayered Rosettes","conceptCode":"C186534","definition":"A central nervous system embryonal tumor characterized by the presence of multilayered rosette formation and typically the presence of amplification of the C19MC region on chromosome 19 (19q13.42) or rarely a DICER1 mutation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E17E3623-9387-491A-E053-731AD00A0CC1","latestVersionIndicator":"Yes","beginDate":"2022-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-22","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B2B-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Glioneuronal and neuronal tumors, NOS or NEC","valueDescription":null,"ValueMeaning":{"publicId":"14235233","version":"1","preferredName":"Glioneuronal and Neuronal Tumors","longName":"14235233v1.00","preferredDefinition":"A group of central nervous system neoplasms with a variable amount of neuronal and, less consistently, glial differentiation. They occur at a low frequency and usually carry a favorable prognosis.  Representative examples include dysplastic cerebellar gangliocytoma, desmoplastic infantile ganglioglioma, desmoplastic infantile astrocytoma, and dysembryoplastic neuroepithelial tumor. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioneuronal and Neuronal Tumors","conceptCode":"C4747","definition":"A group of central nervous system neoplasms with a variable amount of neuronal and, less consistently, glial differentiation. They occur at a low frequency and usually carry a favorable prognosis.  Representative examples include dysplastic cerebellar gangliocytoma, desmoplastic infantile ganglioglioma, desmoplastic infantile astrocytoma, and dysembryoplastic neuroepithelial tumor. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CADF05-E715-2BCD-E063-731AD00A4231","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"LISU","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B2C-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"High-grade glioma, NOS or NEC","valueDescription":null,"ValueMeaning":{"publicId":"14741370","version":"1","preferredName":"Childhood Malignant Glioma","longName":"14741370v1.00","preferredDefinition":"A malignant glioma that occurs during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Malignant Glioma","conceptCode":"C202298","definition":"A malignant glioma that occurs during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A31AAE-9B1F-6E06-E063-731AD00A6D2B","latestVersionIndicator":"Yes","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B2D-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Immunodeficiency-associated CNS lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"14235575","version":"1","preferredName":"Immunodeficiency-Related Central Nervous System Lymphoma","longName":"14235575v1.00","preferredDefinition":"A lymphoma that arises from the central nervous system in patients with acquired immunodeficiency conditions or rarely, hereditary immunodeficiency syndromes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunodeficiency-Related Central Nervous System Lymphoma","conceptCode":"C186658","definition":"A lymphoma that arises from the central nervous system in patients with acquired immunodeficiency conditions or rarely, hereditary immunodeficiency syndromes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF7926-1F60-717F-E063-731AD00A089A","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B2E-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Low-grade glioma, NOS or NEC","valueDescription":null,"ValueMeaning":{"publicId":"14741371","version":"1","preferredName":"Childhood Low Grade Glioma","longName":"14741371v1.00","preferredDefinition":"A low-grade glioma that occurs during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Low Grade Glioma","conceptCode":"C202299","definition":"A low-grade glioma that occurs during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A31AAE-9B20-6E06-E063-731AD00A6D2B","latestVersionIndicator":"Yes","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B2F-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Medulloblastoma, NOS on NEC","valueDescription":null,"ValueMeaning":{"publicId":"14741372","version":"1","preferredName":"Childhood Medulloblastoma","longName":"14741372v1.00","preferredDefinition":"A medulloblastoma occurring in children.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Medulloblastoma","conceptCode":"C3997","definition":"A medulloblastoma occurring in children.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A31AAE-9B21-6E06-E063-731AD00A6D2B","latestVersionIndicator":"Yes","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B30-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Meningeal melanocytic neoplasms (includes melanoma)","valueDescription":null,"ValueMeaning":{"publicId":"14235574","version":"1","preferredName":"Primary Meningeal Melanocytic Neoplasm","longName":"14235574v1.00","preferredDefinition":"A benign, intermediate, or malignant circumscribed or diffuse neoplasm that arises from melanocytes in the leptomeninges.  It includes meningeal melanocytoma, meningeal melanoma, meningeal melanocytoma of intermediate grade, and meningeal melanocytosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Meningeal Melanocytic Neoplasm","conceptCode":"C4661","definition":"A benign, intermediate, or malignant circumscribed or diffuse neoplasm that arises from melanocytes in the leptomeninges.  It includes meningeal melanocytoma, meningeal melanoma, meningeal melanocytoma of intermediate grade, and meningeal melanocytosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01CF7926-1F5F-717F-E063-731AD00A089A","latestVersionIndicator":"Yes","beginDate":"2023-07-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-31","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B31-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Posterior fossa ependymoma, NOS or NEC","valueDescription":null,"ValueMeaning":{"publicId":"14741373","version":"1","preferredName":"Posterior Fossa Ependymoma, Not Otherwise Specified","longName":"14741373v1.00","preferredDefinition":"A circumscribed ependymoma that arises in the posterior fossa in which molecular analysis for DNA methylation profiling was unsuccessful or not reported.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Posterior Fossa Ependymoma, Not Otherwise Specified","conceptCode":"C186449","definition":"A circumscribed ependymoma that arises in the posterior fossa in which molecular analysis for DNA methylation profiling was unsuccessful or not reported.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A31AAE-9B22-6E06-E063-731AD00A6D2B","latestVersionIndicator":"Yes","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B32-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Spinal ependymoma, NOS or NEC","valueDescription":null,"ValueMeaning":{"publicId":"14741374","version":"1","preferredName":"Childhood Spinal Cord Ependymoma","longName":"14741374v1.00","preferredDefinition":"An ependymoma of the spinal cord not associated with MYCN amplification and occurring in children.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Spinal Cord Ependymoma","conceptCode":"C186495","definition":"An ependymoma of the spinal cord not associated with MYCN amplification and occurring in children.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A31AAE-9B23-6E06-E063-731AD00A6D2B","latestVersionIndicator":"Yes","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A31AAE-9B33-6E06-E063-731AD00A6D2B","beginDate":"2024-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-05","modifiedBy":"SOKKERL","dateModified":"2024-02-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"14741262","version":"1","preferredName":"WHO CNS5 Integrated Diagnosis Text","preferredDefinition":"A term that refers to the WHO 5th edition classification of central nervous system neoplasms defined by the combination of molecular diagnostics with histopathological and immunohistochemical findings._The words of something written.","longName":"14741262v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO CNS5 Integrated Diagnosis","conceptCode":"C203770","definition":"A term that refers to the WHO 5th edition classification of central nervous system neoplasms defined by the combination of molecular diagnostics with histopathological and immunohistochemical findings.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10460B8F-72A5-42EB-E063-731AD00A4980","latestVersionIndicator":"Yes","beginDate":"2024-01-31","endDate":null,"createdBy":"COLBERTM","dateCreated":"2024-01-31","modifiedBy":"COLBERTM","dateModified":"2024-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCDI:Childhood Cancer Data Initiative","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"102B2F5D-25A1-6C6F-E063-731AD00A1A20","latestVersionIndicator":"Yes","beginDate":"2024-01-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":"1/30/24 Created per CCDI submission template. mr","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"13574489","version":"1","longName":"Childhood Cancer Data Initiative","context":"Pediatric Cancer","ClassificationSchemeItems":[{"publicId":"14727027","version":"1","longName":"Diagnosis","context":"Pediatric Cancer"},{"publicId":"13594093","version":"1","longName":"Sample","context":"Pediatric Cancer"},{"publicId":"13596241","version":"1","longName":"Diagnosis","context":"Pediatric Cancer"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"WHO CNS5","url":null,"context":"Pediatric Cancer"}],"origin":"CCDI:Childhood Cancer Data Initiative","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"10462B1A-9FBA-4860-E063-731AD00A19D2","latestVersionIndicator":"Yes","beginDate":"2024-01-31","endDate":null,"createdBy":"COLBERTM","dateCreated":"2024-01-31","modifiedBy":"COLBERTM","dateModified":"2024-02-01","changeDescription":null,"administrativeNotes":"1/31/24 Created per CCDI submission template. mr","unresolvedIssues":null,"deletedIndicator":"No"}}